Published in Nucleic Acids Res on January 31, 2007
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A (2013) 1.82
Regulation of the human catalytic subunit of telomerase (hTERT). Gene (2012) 1.81
Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res (2009) 1.65
Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One (2010) 1.61
Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J Cell Biochem (2008) 1.39
Telomeres and immunological diseases of aging. Gerontology (2009) 1.22
Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J (2010) 1.07
Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol (2008) 1.05
BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res (2010) 1.04
The effect of preconception paternal alcohol exposure on epigenetic remodeling of the h19 and rasgrf1 imprinting control regions in mouse offspring. Front Genet (2012) 1.03
A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev Res (Phila) (2011) 0.97
Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4. Oncogene (2012) 0.94
Diet-related telomere shortening and chromosome stability. Mutagenesis (2011) 0.92
5-aza-2'-deoxycytidine-mediated c-myc Down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia. Neoplasia (2014) 0.91
hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer (2010) 0.90
p16(INK4a) -mediated suppression of telomerase in normal and malignant human breast cells. Aging Cell (2010) 0.88
Regulation of Pax6 by CTCF during induction of mouse ES cell differentiation. PLoS One (2011) 0.88
PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. J Pathol (2010) 0.87
An overview of epigenetic assays. Mol Biotechnol (2007) 0.87
Reactivation of telomerase in cancer. Cell Mol Life Sci (2016) 0.87
Depletion of sirtuin 1 (SIRT1) leads to epigenetic modifications of telomerase (TERT) gene in hepatocellular carcinoma cells. PLoS One (2014) 0.86
Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol (2016) 0.83
Longitudinal assessment of DNA methylation changes during HPVE6E7-induced immortalization of primary keratinocytes. Epigenetics (2015) 0.83
Epigenetic linkage of aging, cancer and nutrition. J Exp Biol (2015) 0.83
A role for methyl-CpG binding domain protein 2 in the modulation of the estrogen response of pS2/TFF1 gene. PLoS One (2010) 0.82
Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet (2017) 0.82
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med (2016) 0.82
Retinoid-induced histone deacetylation inhibits telomerase activity in estrogen receptor-negative breast cancer cells. Anticancer Res (2009) 0.81
Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene. Genes (Basel) (2016) 0.79
hTERT methylation is necessary but not sufficient for telomerase activity in colorectal cells. Oncol Lett (2011) 0.79
Telomerase as a useful target in cancer fighting-the breast cancer case. Tumour Biol (2013) 0.79
Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter. J Biol Chem (2013) 0.78
Epigenetic control of metastasis-associated protein 1 gene expression by hepatitis B virus X protein during hepatocarcinogenesis. Oncogenesis (2012) 0.77
Longitudinal epigenetic variation of DNA methyltransferase genes is associated with vulnerability to post-traumatic stress disorder. Psychol Med (2014) 0.77
Diagnostic Value of Methylated Human Telomerase Reverse Transcriptase in Human Cancers: A Meta-Analysis. Front Oncol (2015) 0.77
Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways. J Carcinog Mutagen (2014) 0.77
Epigenetic regulation of telomerase expression in HIV-1-specific CD8+ T cells. AIDS (2010) 0.77
The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies. JAKSTAT (2013) 0.77
Telomerase reverse transcriptase methylation predicts lymph node metastasis and prognosis in patients with gastric cancer. Onco Targets Ther (2016) 0.77
Regulation of the Telomerase Reverse Transcriptase Subunit through Epigenetic Mechanisms. Front Genet (2016) 0.77
DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment. Oncogene (2015) 0.76
Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer. Pharmgenomics Pers Med (2015) 0.75
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Br J Haematol (2016) 0.75
Immortalization of T-cells is accompanied by gradual changes in CpG methylation resulting in a profile resembling a subset of T-cell leukemias. Neoplasia (2014) 0.75
Telomerase Activation in Hematological Malignancies. Genes (Basel) (2016) 0.75
Tianshengyuan-1 (TSY-1) regulates cellular Telomerase activity by methylation of TERT promoter. Oncotarget (2017) 0.75
Association Between Type-specific HPV Infections and hTERT DNA Methylation in Patients with Invasive Cervical Cancer. Cancer Genomics Proteomics (2016) 0.75
Telomerase: The Devil Inside. Genes (Basel) (2016) 0.75
Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. Oncotarget (2016) 0.75
Telomeres and telomerase in prostate cancer development and therapy. Nat Rev Urol (2017) 0.75
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Telomerase catalytic subunit homologs from fission yeast and human. Science (1997) 12.35
The RNA component of human telomerase. Science (1995) 9.86
Applying the principles of stem-cell biology to cancer. Nat Rev Cancer (2003) 8.95
Stem cells and cancer; the polycomb connection. Cell (2004) 7.43
Telomere length regulation. Annu Rev Biochem (1996) 6.98
Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet (1997) 6.69
An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol (1996) 5.74
Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol (2000) 5.34
CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol (1993) 3.08
Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res (1999) 2.74
BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A (2002) 2.62
DNA methylation: past, present and future directions. Carcinogenesis (2000) 2.58
The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet (1999) 2.52
Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res (1999) 2.32
Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene (1999) 2.22
Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene (2001) 1.86
DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res (1999) 1.79
Transcriptional repression by the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res (2000) 1.74
Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res (2001) 1.73
Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol (2004) 1.65
Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer (2002) 1.64
Telomerase activity in normal human epithelial cells. Oncogene (1996) 1.50
The telomere and telomerase: nucleic acid-protein complexes acting in a telomere homeostasis system. A review. Biochemistry (Mosc) (1997) 1.47
Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene (2003) 1.38
Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol (2004) 1.31
Methylation of the human telomerase gene CpG island. Cancer Res (2000) 1.31
CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res (2005) 1.27
Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res (2003) 1.23
Differential cis-regulation of human versus mouse TERT gene expression in vivo: identification of a human-specific repressive element. Proc Natl Acad Sci U S A (2005) 1.21
Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res (2001) 1.18
Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood (1997) 1.18
HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene (2004) 1.16
Molecular cloning of a novel human gene encoding histone acetyltransferase-like protein involved in transcriptional activation of hTERT. Biochem Biophys Res Commun (2003) 1.13
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
A novel transgenic mouse model reveals humanlike regulation of an 8-kbp human TERT gene promoter fragment in normal and tumor tissues. Cancer Res (2005) 1.03
Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. Biochem Biophys Res Commun (2004) 1.02
Control mechanisms in the regulation of telomerase reverse transcriptase expression in differentiating human teratocarcinoma cells. Biochem Biophys Res Commun (2003) 1.01
Methylation status and expression of human telomerase reverse transcriptase mRNA in relation to hypermethylation of the p16 gene in colorectal cancers as analyzed by bisulfite PCR-SSCP. Jpn J Clin Oncol (2002) 0.92
CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol (2002) 0.90
Microdissection by exclusion and DNA extraction for multiple PCR analyses from archival tissue sections. Biotechniques (2000) 0.90
Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin Cancer Res (2000) 0.90
Implication of the exon region in the regulation of the human telomerase reverse transcriptase gene promoter. Biochem Biophys Res Commun (2003) 0.89
Methylation-sensitive single-strand conformation analysis: a rapid method to screen for and analyze DNA methylation. Methods Mol Biol (2004) 0.86
Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. Cancer Res (2005) 0.84
CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet (2001) 6.80
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol (2000) 5.34
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A (1995) 2.70
Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res (1991) 2.39
Gastric and duodenal mucosa in 'healthy' individuals. An endoscopic and histopathological study of 50 volunteers. J Clin Pathol (1978) 2.29
The influence of fixation on immunoperoxidase staining of plasmacells in paraffin sections of intestinal biopsy specimens. Histochemistry (1977) 2.22
For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer (1998) 2.16
Dysplasia classification: pathology in disgrace? J Pathol (2001) 1.94
A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest (1997) 1.74
Transcriptional repression by the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res (2000) 1.74
Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry (1985) 1.73
A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer (1988) 1.72
Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol (1999) 1.62
Regional metastasis in head and neck squamous cell carcinoma: revised value of US with US-guided FNAB. Radiology (1996) 1.59
Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer (1992) 1.56
CpG methylation regulates the Igf2/H19 insulator. Curr Biol (2001) 1.55
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest (2001) 1.46
[A normal cervical smear and yet cervical cancer]. Ned Tijdschr Geneeskd (1992) 1.44
Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol (1997) 1.43
Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer (2001) 1.41
Focal glomerulosclerosis in neonatal kidney grafts. Nephron (1989) 1.40
Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol (1996) 1.36
Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol (1995) 1.32
Evidence for predominant involvement of the B-cell system in the inflammatory process in Crohn's disease. Scand J Gastroenterol (1979) 1.32
An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry. Cytometry (1987) 1.30
Effect of tissue fixation on anti-bromodeoxyuridine immunohistochemistry. J Histochem Cytochem (1987) 1.27
Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J Pathol (1998) 1.27
Type IV collagen immunoreactivity in colorectal cancer. Prognostic value of basement membrane deposition. Cancer (1988) 1.26
K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am J Pathol (1994) 1.23
Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene (2006) 1.22
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer (2008) 1.20
Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res (1994) 1.19
Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma (1983) 1.18
Proliferation and apoptosis in proliferative lesions of the colon and rectum. Virchows Arch (1997) 1.17
p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer (2000) 1.15
Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood (1999) 1.13
Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol (2000) 1.13
Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol Histopathol (1998) 1.10
Gastrointestinal telangietasia as a cause of severe blood loss in systemic sclerosis. Endoscopy (1980) 1.10
Immunohistochemical light and electron microscopy of basal laminar deposit. Graefes Arch Clin Exp Ophthalmol (1994) 1.09
Report of an Amsterdam working group on Barrett esophagus. Virchows Arch (2003) 1.08
Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum (2001) 1.06
DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril. J Mol Cell Cardiol (1991) 1.05
Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol (1993) 1.05
Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer (1993) 1.05
L-CAM expression in normal, premalignant, and malignant colon mucosa. J Pathol (1992) 1.04
Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol (1999) 1.04
Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Res (1987) 1.03
The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg (1998) 1.02
Muscle fiber typing in routinely processed skeletal muscle with monoclonal antibodies. Histochemistry (1990) 1.01
Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol (1995) 1.00
Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer (2000) 1.00
The hamartoma-adenoma-carcinoma sequence. J Pathol (1999) 1.00
Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fertil (1992) 1.00
Clinical applications of the enzyme labeled antibody method. Immunoperoxidase methods in diagnostic histopathology. J Histochem Cytochem (1979) 0.99
p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol (2001) 0.99
Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology, and proliferative activity. Cancer Res (1999) 0.98
Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma. Virchows Arch (2009) 0.97
The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck. Int J Radiat Oncol Biol Phys (1998) 0.97
Curly fiber and tangle-like inclusions in the ependyma and choroid plexus--a pathogenetic relationship with the cortical Alzheimer-type changes? J Neuropathol Exp Neurol (1998) 0.97
Value of cerebrospinal fluid cytology for the diagnosis of malignancies in the central nervous system. J Neurosurg (1978) 0.97
Undifferentiated carcinoma of the colon containing exocrine, neuroendocrine and squamous cells. Virchows Arch A Pathol Anat Histopathol (1983) 0.97
Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res (1995) 0.96
Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol (2000) 0.96
A methylation sensitive dot blot assay (MS-DBA) for the quantitative analysis of DNA methylation in clinical samples. J Clin Pathol (2005) 0.96
Amplification of the nephrotoxic effect of cyclosporine by preexistent chronic histological lesions in the kidney. Transplantation (1989) 0.95
Patterns of alpha- and beta-catenin and E-cadherin expression in colorectal adenomas and carcinomas. J Pathol (1997) 0.94
Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosomes Cancer (1995) 0.94
p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol (1994) 0.94
Promoter methylation analysis on microdissected paraffin-embedded tissues using bisulfite treatment and PCR-SSCP. Biotechniques (2001) 0.94
Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol (2000) 0.94
Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis. J Clin Pathol (1988) 0.94
Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms. J Cell Sci (1999) 0.92
Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest (1997) 0.92
Bromodeoxyuridine (BrdU) immunocytochemistry by exonuclease III (Exo III) digestion. Histochemistry (1992) 0.92
Basement membranes in cancer. Ultrastruct Pathol (1985) 0.91
Mucosal alterations in the reservoir of patients with Kock's continent ileostomy. Scand J Gastroenterol (1987) 0.90
An improved method for rapid screening of DNA mutations by nonradioactive single-strand conformation polymorphism procedure. Biotechniques (1993) 0.90
A comparative evaluation of various invasion assays testing colon carcinoma cell lines. Br J Cancer (1999) 0.90
Microdissection by exclusion and DNA extraction for multiple PCR analyses from archival tissue sections. Biotechniques (2000) 0.90
DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther (2007) 0.89
Photometric determination of the DNA distribution in the 24 human chromosomes. Exp Cell Res (1977) 0.89
The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer (1988) 0.89
CEA-specificity of CEA-reactive monoclonal antibodies. Immunochemical and immunocytochemical studies. Anticancer Res (1986) 0.89
In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br J Cancer (1995) 0.89
The value of secretory component (SC) immunoreactivity in diagnosis and prognosis of colorectal carcinomas. Am J Clin Pathol (1984) 0.89
Adenosine deaminase complexing protein (ADCP) immunoreactivity in colorectal adenocarcinoma. Int J Cancer (1986) 0.89
Expression of telomerase genes correlates with telomerase activity in human colorectal carcinogenesis. J Pathol (2001) 0.89